Loading
Resistance often arrives as the same few mutations. Teaching the immune system to recognise them in advance could remove the escaping cells while they are still rare.
Recurrent resistance alleles such as EGFR T790M, ESR1 hotspot mutations and KRAS secondary mutations create new peptides, absent from normal cells, that may be presented on MHC. An off-the-shelf vaccine or T-cell product against a small set of public resistance neoantigens, given at the start of or during targeted therapy, would apply immune pressure precisely to the cells that are expanding under drug pressure.
Shares Neoantigen, Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Neoantigen, Personalised neoantigen (mRNA) vaccines, No one can predict who responds to immunotherapy.